Clinical Trial

A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy of Entinostat combined with Fulvestrant in HR+/HER2- advanced breast cancer patients with recurrence/progression after endocrine therapy (primary endpoint: progression-free survival \[PFS\]), and explore the correlation between peripheral blood mononuclear cell (PBMC) acetylation levels and treatment response to determine the baseline acetylation threshold .
Trial Details
NCT Number NCT07235618
Lead Sponsor Sun Yat-sen University
Conditions Locally Advanced or Metastatic Breast Cancer
Enrollment 50 participants
Start Date 2026-01-05
Primary Completion 2028-01 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-19